Abrégé

jijij2n-11n1nn).

Classes IPC  ?

• A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The present invention relates to the treatment of Tauopathies. In this study, the inventors worked on an optimized treatment of Tauopathies, including AD and primary Tauopathies. Previously, the inventors evidenced that Tau pathology is associated with deleterious T-cell-mediated processes that contribute to promote Tau-related detrimental neuroinflammation and cognitive deficits. Considering the unique capacity of immunosuppressive Tregs to inhibit both CD4+ and CD8+ T cell responses, the inventors raise the hypothesis that amplifying Tregs may allow controlling Tau-driven T-cell-mediated detrimental processes in the course of AD and other Tauopathies. They thus evaluated preclinically the impact on disease progression of an optimized IL-2-based Treg-targeting immunomodulatory treatment in the THY-Tau22 mouse model of Tauopathy. They chronically treated THY-Tau22 mice with an optimized IL-2-based treatment, i.e. complexes of IL-2 and anti-IL-2 antibodies (termed herein IL-2C) in order to modulate Tau-associated detrimental T cell responses. Their data supports that this treatment amplifies Tregs more efficiently and selectively than "regular" low dose IL-2 treatment. Furthermore, they hereby showed that IL-2C has a beneficial effect on cognitive deficits since treated THY-Tau22 mice tend to acquire and retain spatial information more potently than untreated littermates. Thus, the invention relates to an IL-2/anti-IL-2 complex (IL-2C) for use in the treatment of Tauopathies.

Classes IPC  ?

• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• A61K 38/20 - Interleukines
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present application relates to pyrazole derivatives as PD-1/PD-L1 interaction inhibitors. The applicants designed compounds of general formula (I), wherein R', R2, y3, R3, R4, R5, R6and R7in vitroin vitro biological tests (FRET assay, Promega Blockade assay, T cell assay). These compounds had an affinity (Kd) of the order of pM that was higher than that of the antibody atezolizumab used in clinical use, and had a comparable or better IC50 than that observed with atezolizumab. Thus, the present invention also relates to a pharmaceutical composition comprising said compound(s) and their uses in the treatment of PD-1-PD-L1 interactions-related diseases (cancer, chronic inflammatory diseases, neurological diseases and chronic infections).

Classes IPC  ?

• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 35/00 - Agents anticancéreux
• C07D 231/40 - Atomes d'azote acylés sur ledit atome d'azote
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 403/10 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/5355 - Oxazines non condensées contenant d'autres hétérocycles

Abrégé

METHODS OF TREATMENT OF METABOLIC DISORDERS In the present invention SLC5A9 gene (encoding SGLT4 protein) regulation was analyzed in the intestine of patients before and after weight-loss surgery. RNA scope analysis was used to determine the precise location of SLC5A9 in the human intestine and pancreas. Sglt4 knock- out (KO) mice were created using CRISPR/Cas techniques, allowing to study changes in their metabolic phenotype for months while they were fed the WD (Western Diet). So, these data demonstrate that SLC5A9 mRNA levels are induced in the apical membrane of the intestine and exocrine pancreas in persons with obesity and Type 2 Diabetes. Furthermore, Sglt4 deficiency slows the onset of obesity and hyperglycemia in mice fed the WD, improving insulin sensitivity by improving beta cell function. Accordingly the present invention relates to a method for preventing or treating metabolic disorders by targeting the Sodium-Glucose-Co- Transporter-4 (SGTL4).

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C40B 30/06 - Procédés de criblage des bibliothèques en mesurant les effets sur des cellules, des tissus ou des organismes vivants
• G01N 33/15 - Préparations médicinales
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
• A61P 5/48 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins

Abrégé

LDLrLDLr -/-PPARαLDLrLDLr -/- PPARαPPARα +/+LDLrLDLr -/- PPARαPPARα -/-LDLrLDLr -/- PPARαPPARα +/+LDLrLDLr -/- PPARαPPARα +/+LDLrLDLr -/- PPARαPPARα +/+ mice. The present invenion defines a new relevant mouse model of progressive MASLD, developing all the characteristics of human MASLD (steatosis, inflammation, ballooning, fibrosis), in a relatively short time period (12-18 weeks), along with simultaneous atherosclerosis development.

Classes IPC  ?

• A01K 67/0276 - Vertébrés knock-out

Abrégé

Provided are closed systems methods of use for isolation of mammalian tissues.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The invention concerns a new galenic formulation of CFT (clofoctol) allowing the administration of this antibiotic in aerosol form with the objective of treating pulmonary infections (COVID-19, influenza), cancer and inflammation thus targeting the diseased tissue while avoiding the problems of solubility of CFT and toxicity associated with this drug. This new formulation allows to answer these problems and concerns the development of polymeric nanoparticles (Nanoparticles) in suspension in an aqueous phase intended to be administrated in a form of aerosol or spray, said Nanoparticles comprising PLGA and PLGA-PEG polymers, allowing to obtain an effective encapsulation of CFT and a controlled release of CFT at the pulmonary level.

Classes IPC  ?

• A61K 9/51 - Nanocapsules

Abrégé

The present invention proposes a method for manufacture of an endoprosthesis, in particular a vascular endoprosthesis, comprising the 3D printing (100) of a hollow membrane made of thermoplastic elastomer, and the fastening (200) of a collapsible metal framework to the hollow membrane in order to form a membrane-framework assembly. The fastening comprises (i) the 3D printing (201) of an additional membrane made of thermoplastic elastomer, the arranging (202) of the collapsible metal framework between the hollow membrane and the additional membrane in order to obtain an assembly, the immersion soaking (204) of the assembly in an organic solvent in order to obtain the membrane-framework assembly, and the drying (205) of the membrane-framework assembly; or (ii) the arranging (212) of the collapsible metal framework on the hollow membrane in order to obtain an assembly, and the dip coating (214) in a solution in an organic solvent, and then the drying (215) of the assembly.

Classes IPC  ?

• A61F 2/07 - Endoprothèses déployables couvertes

Abrégé

The present disclosure relates to conjugates of catechol-based siderophores with cargo molecules, such as antibiotics or fluorophores, and to the preparation and uses thereof.

Classes IPC  ?

• A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
• A61K 49/00 - Préparations pour examen in vivo
• A61P 31/04 - Agents antibactériens
• C07D 211/94 - Atome d'oxygène, p. ex. N-oxyde de pipéridine
• C07D 223/12 - Atomes d'azote ne faisant pas partie d'un radical nitro
• C07D 277/10 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
• C07D 323/00 - Composés hétérocycliques contenant plus de deux atomes d'oxygène comme uniques hétéro-atomes du cycle
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 473/18 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 un atome d'oxygène et un atome d'azote, p. ex. guanine
• C07D 473/34 - Atome d'azote lié en position 6, p. ex. adénine
• C07D 491/16 - Système condensés en péri
• C07D 493/10 - Systèmes condensés en spiro
• C07D 498/08 - Systèmes pontés
• C07D 499/64 - Composés avec un radical amino acylé par des acides carboxyliques, lié en position 6 avec une chaîne carbonée, substituée par des hétéro-atomes ou par des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, liée au radical carboxamido substituée en position alpha du radical carboxamido par des atomes d'azote

Abrégé

Glutamatergic neurons produce, accumulate and release in synapses the neurotransmitter glutamate, which is the main excitatory neurotransmitter in the mammalian central nervous system. Said neurons are involved in most of the brain's fundamental processes such as cognition, learning, memory, and sensory perception. There is an interest to identify transcription factor that would allow the differentiation towards glutamatergic neurons. The inventors surprisingly show that overexpression of ASCL1 induces the generation of a highly pure population of glutamatergic neurons. Said observation goes totally in the opposite direction of what has been previously taught, since ASLC1 was mainly described as inducing GABAergic neurons in the forebrain. Therefore, the present invention relates to methods for generating highly pure glutamatergic neuronal populations using the pro-neural factor ASCL1.

Classes IPC  ?

• C12N 5/0793 - Neurones

Abrégé

The present invention pertains to an inner ear implant for controlled release of an active ingredient comprising the active ingredient and polyethylene vinyl acetate (EVA).

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone

Abrégé

The present disclosure relates to a controlled release delivery dosage form for controlled release of an active ingredient, comprising a core comprising said active ingredient, coated by a polymeric mixture of at least a water insoluble polymer, and at least a polysaccharide extract selected from the group consisting of aqueous aloe vera extract and aqueous reishi extract, their methods of producing and uses thereof.

Classes IPC  ?

• A61K 9/50 - Microcapsules
• A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino

Abrégé

The gut-to-lung axis is critical during respiratory infections, including influenza A virus (IAV) infection. In the present study, the inventors used high-resolution shotgun metagenomics and targeted metabolomics analyses to characterize influenza-associated changes in the mouse gut microbiota's composition and metabolism. Quantitative targeted metabolomics analysis of serum revealed changes in specific classes of gut microbiota metabolites, including SCFAs, indole-containing tryptophan metabolites, trimethylamine, and polyamines. The changes in microbiota-associated metabolites were correlated with changes in taxon abundances and levels of disease markers. For instance, the tryptophan metabolite indole-3-propionic acid (IPA) was correlated positively with some Bacillota species but negatively with Bacteroidales bacteria M7, the viral load, and inflammation markers. Given its marked fall during infection, the inventors tested the effects of IPA supplementation in diseased animals. This supplementation was associated with a lower viral load and lower levels of local (lung) and systemic inflammation during influenza. Taken as a whole, the results highlighted IPA as both an important metabolic modulator to disease severity and a potential biomarker of influenza outcomes.

Classes IPC  ?

• A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The invention relates to a microfluidic device (1) for forming a cell assembly comprising at least one first cell (C1) and one second cell (C2) and for individually treating a selected cell of said cell assembly, comprising: - a microfluidic channel (10); - at least one main inlet (11) for a fluid containing first cells, respectively second cells, arranged in a first portion (101) of the microfluidic channel; - an outlet (12) arranged in a second portion (102) of the microfluidic channel for controlling a fluid flow rate in the microfluidic channel; - at least one first auxiliary inlet (131) for a first auxiliary fluid arranged in the first portion (101) of the microfluidic channel upstream or downstream of the main inlet (11); - at least one cell trap (14) arranged in the microfluidic channel between the first portion and the second portion, wherein each cell trap (14) comprises at least one first trapping portion (141) and one second trapping portion (142), each first and second trapping portion being sized to receive a respective first or second cell, said first and second trapping portions being adjacent to each other in a direction perpendicular to a bottom (100) of the microfluidic channel to form the cell assembly with the trapped first and second cells, each cell being at a different height relative to the bottom of the microfluidic channel, - at least one first valve for controlling a flow rate of the first auxiliary fluid so as to cause the fluid containing the first cells, respectively the second cells, to flow at a determined height in the microfluidic channel in order to bring the first cell, respectively the second cell, to the first trapping portion, respectively to the second trapping portion.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Abrégé

Therapeutic resistance is one of the major challenges in cancer treatment. These latter may be inherently resistant or this resistance may be acquired during treatment. In this context, the tau protein, encoded by the MAPT gene, could prove to be an important contributor in resistance to cancer therapy. The inventors have been thus abled to confirm in vivo that the tau protein was a factor of resistance to radiotherapy and the chemotherapy inducing DSB (doxorubicin) and that the reduction of its expression by shRNA increased the sensitivity of tumors to these treatments. The present invention relates to a method for decreasing therapeutic acquired resistance to chemotherapy agent and/or radiotherapy agent in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a Tau inhibitor.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 35/00 - Agents anticancéreux
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider

Abrégé

ApicomplexaToxoplasmaT. gondii T. gondii T. gondii morphology and inhibiting intracellular replication. The findings highlight the advantage of comparative and targeted phenotypic analysis involving two related parasite species as a means of identifying molecules with a conserved mode of action.

Classes IPC  ?

• C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
• A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• C07K 14/45 - Toxoplasma
• C12N 1/10 - ProtozoairesLeurs milieux de culture
• C12N 15/09 - Technologie d'ADN recombinant
• G01N 21/00 - Recherche ou analyse des matériaux par l'utilisation de moyens optiques, c.-à-d. en utilisant des ondes submillimétriques, de la lumière infrarouge, visible ou ultraviolette
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

BlastocystisBlastocystisBlastocystisBlastocystis sp. in fecal samples obtained from heifers, for predicting productive longevity in heifers, and for improving dairy herd management.

Classes IPC  ?

• C12Q 1/6893 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les protozoaires

Abrégé

The inventors have now succeeded in developing novel compounds comprising a diphenylpyrazole scaffold bearing amino side chains. These compounds have the advantage of repressing the production of Aβ1-x and modulating the ratio of autophagy markers with higher efficacy than chloroquine and compounds of the prior art, in particular compounds of the prior art, The present invention is thus directed to compounds of Formula (I) including their pharmaceutically acceptable salts and solvates which have the ability to repress the production of Aβ1-x peptides and to modulate the ratio of autophagy markers, and which are useful as therapeutic compounds, particularly in the treatment and/or prevention of diseases involving the formation of amyloid plaques and/or in which dysfunction of the APP metabolism occurs.

Classes IPC  ?

• A61K 31/415 - 1,2-Diazoles
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07D 231/22 - Un atome d'oxygène lié en position 3 ou 5 avec des radicaux aryle liés aux atomes d'azote du cycle

Abrégé

The present invention relates to a surgical insert (1) comprising a first layer (11), and a second layer (12), wherein the first layer and the second layer comprise orifices (111, 121) having an eight shape.

Classes IPC  ?

• A61F 2/30 - Articulations
• A61B 17/60 - Instruments ou procédés chirurgicaux pour le traitement des os ou des articulationsDispositifs spécialement adaptés à cet effet pour ostéosynthèse, p. ex. plaques, vis ou matériels de fixation pour l'ostéosynthèse externe, p. ex. appareils étireurs ou constricteurs

Abrégé

The present invention relates to a surgical insert (1) comprising a first layer (11) and a second layer (12), wherein the first layer and the second layer comprise openings (111, 112) having a figure-of-eight shape. The invention also relates to a bone cement comprising a pulverulent solid phase that comprises natural polysaccharides and a ceramic filler, a liquid acrylate, and a polymerising agent.

Classes IPC  ?

• A61F 2/30 - Articulations
• A61L 27/10 - Céramiques ou verres
• B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive

Abrégé

Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cells and evaluated Sig-1R implication in stromal cues integration by PCC from signaling transmission to biological outcomes, at the cellular and physiological level. They demonstrated that the loss of Sig-1R in epithelial cells inhibits stromal-induced tumor growth and metastatic process. Thus, the inventors demonstrate that Sig-1R is a key actor of the dialog between stromal and cancer cell compartments The present invention relates to method for the treatment of pancreatic cancer in a patient in need thereof comprising a therapeutically effective amount of a Sig-1R ligand.

Classes IPC  ?

• A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure relates to a hydrogel composition based on anionic cyclodextrin polymers and chitosan for use in the treatment of articular disorders. In particular, the hydrogel combines a pharmacological action, in particular an analgesic action, with a visco- supplementation (a lubricating effect).

Classes IPC  ?

• A61L 27/26 - Mélanges de matériaux macromoléculaires
• A61L 27/52 - Hydrogels ou hydrocolloïdes
• A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques

Abrégé

Chronic obstructive pulmonary disease is a major clinical challenge mostly due to cigarette smoke exposure and affects more than 200 million people. The inventors tested if exposure to the Bordetella pertussis BPZE1 stain could modulate outcomes of chronic exposure to cigarette smoke in mice. In particular, they showed in mice chronically exposed to cigarette smoke that preventive and/or curative vaccination using BPZE1 could limit the lung inflammation and strongly contribute to the prevention of lung function decline. BPZE1 vaccination modulated pulmonary antigen presenting cells (macrophages and dendritic cells) to switch the immune response, by decreasing the IL-17 inflammatory pathway involved in the pathology of COPD itself, and by favouring a tolerogenic response (IL-10). Together, the data show that vaccination with BPZE1 of mice chronically exposed to cigarette smoke limits the development of chronic obstructive pulmonary disease outcomes and thus represents an interesting therapy.

Classes IPC  ?

• A61K 39/02 - Antigènes bactériens
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• C12N 1/36 - Adaptation ou atténuation de cellules
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C07K 14/235 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Bordetella (G)
• A61K 35/74 - Bactéries
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• C12N 9/10 - Transférases (2.)
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12R 1/01 - Bactéries ou actinomycètes
• C12N 1/20 - BactériesLeurs milieux de culture

Abrégé

Exacerbation of heart failure, better known as acute decompensated heart failure (HF), is characterized by dyspnea, edema and fatigue, and is a growing medical problem. The inventors demonstrated that transient O-GlcNAcase inhibition would be suitable for the treatment of acute decompensated heart failure. In particular they used two recently developed models mimicking acute decompensation of heart failure patients, and deciphered mechanisms susceptible to be involved in this cardiovascular protection, with a focus on post-translational cardiac protein modifications and metabolic remodeling. Accordingly, the present invention relates to the use of O-GlcNAcase inhibitors for the treatment of acute decompensated heart failure.

Classes IPC  ?

• A61K 31/429 - Thiazoles condensés avec des systèmes hétérocycliques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque

Abrégé

In the present invention, inventors demonstrate that prenatal excess of anti-Müllerian hormone triggers PCOS-like impairment in female sexual behavior in mice. Sexual dysfunction in PCOS-like mice is associated with decreased expression of neuronal nitric oxide synthase (nNOS) neurons in different hypothalamic regions known to be involved in female sexual behavior: rostral periventricular area of the third ventricle (RP3V), ventromedial nucleus of the hypothalamus (VMH), and arcuate nucleus (ARN) during estrus. Chemogenetic inhibition of nNOS neuronal activity in the ventromedial nucleus of the hypothalamus of control adult females recapitulates PCOS-like sexual dysfunction. Of clinical relevance, administration of nitric oxide (NO) donor rescues normal sexual behavior in PCOS-like mice. Accordingly, the present invention relates to invention relates to Nitric Oxyde (NO) agent for use in the prevention or the treatment of sexual dysfunction associated with Polycystic Ovary Syndrome (PCOS) or with Hypoactive Sexual Desire Disorder (HSDD) in a subject in need thereof.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs

Abrégé

The invention relates to a device for trapping at least one cell pair in a solution containing at least one first cell (C1) of a first type and at least one second cell (C2) of a second type, comprising: - a microfluidic channel (3) adapted for a unidirectional flow (F) of the solution; - a first trap (1) comprising a pair of first fingers (10a, 10b) arranged in the microfluidic channel (3), at least one of said first fingers (10a, 10b) being coupled to a respective first actuator (11a, 11b), said first actuator being configured to adjust the first trap (1) along a direction transversal to the flow (F) between an open position allowing passage of the first cell between the first fingers (10a, 10b) and a closed position adapted to a size of the first cell to allow trapping the first cell between the first fingers (10a, 10b);15 - a second trap (2) comprising a pair of second fingers (20a, 20b) arranged in the microfluidic channel (3), at least one of said second fingers (20a, 20b) being coupled to a respective second actuator (21a, 21b), said second actuator being configured to adjust the second trap (2) along a direction transversal to the flow (F) between an open position allowing passage of the second cell between the second fingers (20a, 20b) and a closed position adapted to a size of the second cell to allow trapping the second cell between the second fingers (20a, 20b); wherein the first trap (1) is arranged relative to the second trap (2) so as to form, when the first and second traps are in the closed position, a cell pair comprising the trapped first and second cells such that the second cell is in physical or chemical interaction with the first cell.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Abrégé

In the present invention inventors perform studies on extracellular vesicles isolated from urine samples to assess the biomarker potential of measures of the LRRK2-Rab pathway in idiopathic and LRRK2 linked PD as well as in inhibitor dosed rodents and non-human primates. Their results show modifications in the LRRK2-Rab pathway in urinary EVs, both in disease and after LRRK2 kinase inhibitor treatment. More preciasly inventors have found in a first cohort that pS1292-LRRK2 levels were elevated in individuals carrying the LRRK2 G2019S mutation, but did not differ significantly between healthy and PD groups, whether for LRRK2 G2019S carriers or not. In a second cohort, they found that PD was statistically associated to and increase in Rab8 levels and a decrease in S910-LRRK2 and S935-LRRK2 phosphorylation rates. This study assesses LRRK2 and Rabs as a disease and pharmacodynamic marker in human urine samples and this current analysis shows LRRK2 and Rab epitopes modified in patient groups.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Cisplatin is a potent chemotherapeutic drug, widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, such as neuropathy. Therefore, there is an urgent medical need to identify novel strategies limiting cisplatin-induced pain. Here, the inventors provide evidence that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW-6002) significantly protects from cisplatin-induced neuropathy in experimental models of sub-chronic cisplatin treatment. In particular, the present invention relates to a method for the treatment of neuropathy (e.g. CIPN) in a subject in need therefore comprising administering to the subject a therapeutically effective amount of a selective A2A Adenosine Receptor (A2AR) antagonist.

Classes IPC  ?

• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• A61K 33/243 - PlatineSes composés
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
• A61P 35/00 - Agents anticancéreux

Abrégé

2A2A2A2AR) antagonist.

Classes IPC  ?

• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 33/243 - PlatineSes composés
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to an adhesive composition comprising a calcium phosphate ceramic selected from tetracalcium phosphate and alpha-tricalcium phosphate, phosphorylated serine, polydopamine, and an aqueous solvent. The invention also relates to a kit, to a method for producing said adhesive composition as well as to the uses thereof.

Classes IPC  ?

• A61L 24/00 - Adhésifs ou ciments chirurgicauxAdhésifs pour dispositifs de colostomie

Abrégé

Disclosed are modified cytokines which, relative to wild-type forms, comprise one or more amino acid modifications. Relative to the activity of wild type cytokines, these modified cytokines exhibit enhanced activity at an acidic pH and often reduced activity at neutral pH. The disclosed modified cytokines are for use in medicine and/or for the treatment and/or prevention of an immunological condition or cancer.

Classes IPC  ?

• C07K 14/55 - IL-2

Abrégé

Agents for the treatment of patients having non-small cell lung cancer and methods of diagnostics related include an inhibitor of miR 24 3p, a locked nucleic acid, including methods of predicting response to platinum-based chemotherapy, for patients having, or suspected of having, non-small cell lung cancer.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 33/243 - PlatineSes composés
• A61P 35/00 - Agents anticancéreux
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to a device for collecting a fraction of the perspiration excreted by a subject, said device being of the type comprising a multi-layer patch (1) comprising: - a first layer (61, 62, 4) comprising at least one perspiration-collecting aperture (611) and a transfer opening (41); - a hydrophilic absorbent layer (5), positioned above the first layer and communicating with the external environment, and communicating with the first layer via the transfer opening (41); - a film (7), possibly transparent, that constitutes a barrier against water and against vapour and that covers at least the upper face of the absorbent layer (5); said device notably comprising means (6) for regulating the rate at which perspiration in the liquid and/or vapour state penetrates the absorbent layer (5).

Classes IPC  ?

• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge

Abrégé

The present invention relates to a method for rapid detection or quantification of viral particles in a sample. This method is particularly useful for rapid test of SARS-CoV-2.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention relates to a device for detecting a pressure, of the type comprising a detection element on which a pressure is exerted, a transducer connected to said detection element and an elastically deformable shell. Characteristically, according to the invention, said shell (1) is made of biocompatible and sterilisable material, has two opposing walls (11; 19) and an insertion opening (13), and said detection element comprises at least one elastically deformable tube (7), said tube comprises a portion arranged in said shell (1), said tube is closed at one end (71) and filled with a fluid, the other end of said tube being open, arranged outside said shell (1) and connected to said transducer (3).

Classes IPC  ?

• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 17/44 - Forceps obstétricaux

Abrégé

The present invention relates to a pharmaceutical composition comprising propofol and at least one cyclodextrin and/or a cyclodextrin derivative. Characteristically, according to the invention, it further comprises at least one pharmaceutically acceptable salt, with the exception of basic and/or acidic pharmaceutically acceptable salts.

Classes IPC  ?

• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit

Abrégé

The present invention relates to methods for detecting a target in a sample using mutated nanobodies, wherein an amino acid present in the loop of the FR1 region of framework of the nanobodies is mutated to cysteine.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61K 39/44 - Anticorps liés à des supports

Abrégé

The invention is in the field of the treatment of non-small cell lung cancer. The invention provides agents for the treatment of patients having non-small cell lung cancer and methods of diagnostics related, including methods of predicting response to platinum-based chemotherapy, for patients having, or suspected of having, non-small cell lung cancer.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
• C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation

Abrégé

The present invention concerns an in vitro method for diagnosing invasive candidiasis (IC) in a subject which comprises detecting the presence of a Candida glycan and detecting the presence of antibody directed against a protein selected from the group consisting of fructose bisphosphate aldolase (Fba1), enolase 1 (Eno1), heat shock protein 90 (Hsp90), hyphal wall protein (Hwp1), and mannoprotein 65 (Mp65) in a blood, plasma or serum sample of the subject. The invention also relates to a method of determining a suitable treatment regimen for a patient and to a kit for implanting the methods described herein.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus